Development and preclinical evaluation of a vaccine targeting IL‐4 and IL‐13 for the treatment of allergic asthma-Reference-Cited by-同舟云学术

Development and preclinical evaluation of a vaccine targeting IL‐4 and IL‐13 for the treatment of allergic asthma

Published:2021-07-18 Issue:11 Volume:76 Page:3553-3555
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Conde Eva¹²,Bruhns Pierre¹,Serra Vincent²,Reber Laurent L.³^ORCID

Affiliation:

1. Institut Pasteur Unit of Antibodies in Therapy and Pathology UMR 1222 INSERM Paris France

2. Neovacs SA Paris France

3. Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291CNRS UMR5051University Toulouse III Toulouse France

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14998

Reference10 articles.

1. Type 2 inflammation in asthma — present in most, absent in many

2. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease

3. Grouard‐VogelG Conde GarciaE BertrandR et al.WO2019228674A3: Immunogenic product comprising il‐4 and/or il‐13 for treating disorders associated with aberrant il‐4 and/or il‐13 expression or activity;2020.

4. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197

5. Control of allergic reactions in mice by an active anti-murine IL-4 immunization

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A vaccine targeting human IL‐4 and IL‐13 protects against asthma in humanized mice;Allergy;2023-03

2. Pharmacological approaches to target type 2 cytokines in asthma;Pharmacology & Therapeutics;2022-09